- BioDuro has completed the sale of its Irvine-based drug product facility to Forma Life Sciences.
- The company said the transaction does not alter its US identity or headquarters location and supports a sharper focus on core capabilities.
BioDuro has completed the sale of its Irvine-based drug product facility to Forma Life Sciences, an entity formed by BioSelective Capital Investments and Shayan Enterprises, LLC. The divestiture marks a portfolio adjustment as the company concentrates on drug discovery and drug substance development and manufacturing.
The company stated that the transaction does not change its identity or strategic footprint in the United States. BioDuro remains a US company, with its global headquarters continuing to be based in Irvine, California.
“This divestiture is a strategic step that allows BioDuro to further sharpen our focus on our core strengths in drug discovery and drug substance development and manufacturing.”
Dr Armin Spura, CEO of BioDuro
BioDuro added that it continues to maintain a dedicated drug product team in China, focused on supporting IND filings and early clinical programmes for global customers. The team remains part of the company’s integrated development capabilities, particularly for first-in-human and early-stage clinical work.
The company said it remains committed to providing integrated services across discovery, process development and manufacturing, supporting customers worldwide through its CDMO and contract manufacturing model while maintaining scientific and regulatory standards.
